CLX-0901(CLX-0901) - 药物靶点：Tyrosine kinase_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Tyrosine kinase

作用机制

Tyrosine kinase inhibitors、胰岛素增敏剂

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病

原研机构

Theracos, Inc.

在研机构-

非在研机构

PHARMARESEARCH BIO Co., Ltd.

Theracos, Inc.

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 CLX-0901 相关的临床结果

登录后查看更多信息

100 项与 CLX-0901 相关的转化医学

登录后查看更多信息

100 项与 CLX-0901 相关的专利（医药）

登录后查看更多信息

2

项与 CLX-0901 相关的文献（医药）

2001-05-01·Current opinion in investigational drugs (London, England : 2000)

CLX-0901 (Calyx Therapeutics).

Review

作者: Barlocco, D

Calyx Therapeutics is developing the insulin sensitizer, CLX-0901, as an antidiabetic agent. CLX-0901 is the synthetic analog of CLX-0900 which was originally isolated from a plant source. Phase I and toxicological studies indicate that the compound is safe and well tolerated [363764]. As of March 2001, phase II studies had commenced [402737]. Other antidiabetics being investigated by Calyx include CLX-0301, CLX-0921, CLX-0940, CLX-0100 and CLX-0101 [376032].

2000-08-01·IDrugs : the investigational drugs journal

Obesity: Adipogenesis and Insulin Resistance.

Article

作者: Sethi, J K

This meeting focused on the recent developments in the fields of adipogensis and insulin resistance. In particular, the molecular mechanisms presented were those that are likely to be relevant as drug discovery targets for the treatment of obesity and diabetes. New compounds included the LIFR antagonist, hLIF05, and LG- 100641, a selective antagonist of PPARgamma but with insulin sensitizing actions in adipocytes. The small insulin sensitizers discussed were CLX-0901, isolated from plant extracts and currently in phase I clinical trials, TLK-17411, a small synthetic compound and S-15261, which increases insulin sensitivity.

100 项与 CLX-0901 相关的药物交易

登录后查看更多信息